Apimeds Pharmaceuticals US, Inc. (APUS): Nasdaq/NYSE listing notice — Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues

Apimeds Pharmaceuticals US, Inc.

Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.
Has initial 6-month cure period until October 15, 2026; expects to file 10-K by April 30.
Common stock trades with '.LF' designation; trading halt from April 2 remains in effect.
If not cured, NYSE may grant up to 6 additional months or commence delisting procedures.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Apimeds Pharmaceuticals US, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).

Exchange: nyse american
Notice: deficiency notice
Deficiency: late filing
Rules: 1007

Exact text from the filing

April 17, 2026, Apimeds Pharmaceuticals US, Inc. (the “ Company ”) received a notice from the NYSE Regulation staff of the New York Stock Exchange (“ NYSE ”) indicating that the Company is not in compliance with NYSE’s continued listing requirements under the timely filing criteria outlined in Section 1007 of the NYSE American Listed Company Manual as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “ Form 10-K ”). NYSE informed the Company that the Company will have an initial cure period of six months from April

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Apimeds Pharmaceuticals US, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-046671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.